Macrophage MicroRNA-155 promotes cardiac hypertrophy and failure

Background—Cardiac hypertrophy and subsequent heart failure triggered by chronic hypertension represent major challenges for cardiovascular research. Beyond neurohormonal and myocyte signaling pathways, growing evidence suggests inflammatory signaling pathways as therapeutically targetable contribut...

Full description

Saved in:
Bibliographic Details
Main Authors: Heymans, Stephane (Author) , Grimm, Dirk (Author) , Schürmann, Nina (Author)
Format: Article (Journal)
Language:English
Published: 16 Aug 2013
In: Circulation
Year: 2013, Volume: 128, Issue: 13, Pages: 1420-1432
ISSN:1524-4539
DOI:10.1161/CIRCULATIONAHA.112.001357
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1161/CIRCULATIONAHA.112.001357
Verlag, lizenzpflichtig, Volltext: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.112.001357
Get full text
Author Notes:Heymans Stephane, Corsten Maarten F., Verhesen Wouter, Carai Paolo, van Leeuwen Rick E.W., Custers Kevin, Peters Tim, Hazebroek Mark, Stöger Lauran, Wijnands Erwin, Janssen Ben J., Creemers Esther E., Pinto Yigal M., Grimm Dirk, Schürmann Nina, Vigorito Elena, Thum Thomas, Stassen Frank, Yin Xiaoke, Mayr Manuel, de Windt Leon J., Lutgens Esther, Wouters Kristiaan, de Winther Menno P.J., Zacchigna Serena, Giacca Mauro, van Bilsen Marc, Papageorgiou Anna-Pia, and Schroen Blanche
Description
Summary:Background—Cardiac hypertrophy and subsequent heart failure triggered by chronic hypertension represent major challenges for cardiovascular research. Beyond neurohormonal and myocyte signaling pathways, growing evidence suggests inflammatory signaling pathways as therapeutically targetable contributors to this process. We recently reported that microRNA-155 is a key mediator of cardiac inflammation and injury in infectious myocarditis. Here, we investigated the impact of microRNA-155 manipulation in hypertensive heart disease.Methods and Results—Genetic loss or pharmacological inhibition of the leukocyte-expressed microRNA-155 in mice markedly reduced cardiac inflammation, hypertrophy, and dysfunction on pressure overload. These alterations were macrophage dependent because in vivo cardiomyocyte-specific microRNA-155 manipulation did not affect cardiac hypertrophy or dysfunction, whereas bone marrow transplantation from wild-type mice into microRNA-155 knockout animals rescued the hypertrophic response of the cardiomyocytes and vice versa. In vitro, media from microRNA-155 knockout macrophages blocked the hypertrophic growth of stimulated cardiomyocytes, confirming that macrophages influence myocyte growth in a microRNA-155-dependent paracrine manner. These effects were at least partly mediated by the direct microRNA-155 target suppressor of cytokine signaling 1 (Socs1) because Socs1 knockdown in microRNA-155 knockout macrophages largely restored their hypertrophy-stimulating potency.Conclusions—Our findings reveal that microRNA-155 expression in macrophages promotes cardiac inflammation, hypertrophy, and failure in response to pressure overload. These data support the causative significance of inflammatory signaling in hypertrophic heart disease and demonstrate the feasibility of therapeutic microRNA targeting of inflammation in heart failure.
Item Description:Gesehen am 07.05.2021
Physical Description:Online Resource
ISSN:1524-4539
DOI:10.1161/CIRCULATIONAHA.112.001357